Abieta-8,11,13-trien-18-amine → HCID 57345173, compound

HRID 1627238Notes

Reaction equation

HRID 1627238 reaction equation
[CH3:1][CH:2]([C:4]1[CH:9]=[CH:8][C:7]2[C:10]3([CH3:21])[CH:15]([CH2:16][CH2:17][C:6]=2[CH:5]=1)[C:14]([CH2:19][NH2:20])([CH3:18])[CH2:13][CH2:12][CH2:11]3)[CH3:3].C[CH:23]([C:25]1[CH2:38][CH2:37][C@H:36]2[C:27](=CC[C@@H]3[C@]2(C)CCC[C@]3(CN)C)[CH:26]=1)C.CC(C1CC[C@H]2C(=CC[C@@H]3[C@]2(C)CCC[C@]3(CO)C)C=1)C.C[C@]1(CO)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C[C@]1(CN)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C[C@]1(C(N)=O)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.CNC([C@@]1(C)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1)=O.C[C@]1(CNC)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.C(N(CC)C([C@@]1(C)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1)=O)C.C[C@]1(CN(CC)CC)C2[C@@](C)(C3C(=CC2)C=C(C(C)C)CC3)CCC1.CC(C1C=CC2C3(C)C(CCC=2C=1)C(CN)(C)CCC3)C.C[C@]1(CN)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C(F)(F)F)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C[C@]1(CNC(=O)C(Br)(Br)Br)C2[C@@](C)(C3C(CC2)=CC(C(C)C)=CC=3)CCC1.C(C1C=C2C([C@]3(C)C(CC2)[C@@](CNC(=O)C2C=CC=CC=2)(C)CCC3)=CC=1)(C)C>>[CH2:23]([NH:20][CH2:19][C@@:14]1([CH3:18])[CH:15]2[C@@:10]([CH3:21])([C:7]3[C:6]([CH2:17][CH2:16]2)=[CH:5][C:4]([CH:2]([CH3:1])[CH3:3])=[CH:9][CH:8]=3)[CH2:11][CH2:12][CH2:13]1)[C:25]1[CH:38]=[CH:37][CH:36]=[CH:27][CH:26]=1

Participants

16

Reactant 15

HCID 106831Abieta-8,11,13-trien-18-amineHCID 443474Abietyl alcoholHCID 6427963HCID 6427963, compoundHCID 44152028Abietylamine2×HCID 57345061HCID 57345061, compoundHCID 57345062HCID 57345062, compoundHCID 57345063HCID 57345063, compoundHCID 57345064HCID 57345064, compoundHCID 57345065HCID 57345065, compoundHCID 57345104HCID 57345104, compoundHCID 57345169HCID 57345169, compoundHCID 57345170HCID 57345170, compoundHCID 57345171HCID 57345171, compoundHCID 57345172HCID 57345172, compoundHCID 131731674HCID 131731674, compound

Product 1

HCID 57345173HCID 57345173, compound

Procedure

Anti-cancer pharmaceutical liposome compositions including one or more anti-cancer compositions selected from the group consisting of: leelamine, abietylamine, abietyl alcohol/GPR-8/[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methanol; abietylamine/GPR-3/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}amine; abieticamide/GPR-2/(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N-methylabieticamide/GPR-6/(1R,4aR)—N,1,4a-trimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N-methylabietylamine/GPR-7/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}(methyl)amine; N,N-diethylabieticamide/GPR-11/(1R,4aR)—N,N-diethyl-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxamide; N,N-diethylabietylamine/GPR-12/{[(1R,4aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthren-1-yl]methyl}diethylamine; leelamine/[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methanamine; N-acetylleelamine/GPR-4L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}acetamide; N-trifluoroacetylleelamine/GPR-1L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}-2,2,2-trifluoroacetamide; N-tribromoacetylleelamine/GPR-5L/N-{[(1R,4aS)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl]methyl}-2,2,2-tribromoacetamide; N-benzoylleelamine/GPR-7L/N-(((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methyl)benzamide; and N-benzylleelamine/GPR-8L/N-benzyl-1-((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanamine, are provided according to aspects of the present invention.

Sources & evidence

ORD record
ord-808018cde103425b9d5a68c47ff9b8c4
Source dataset
uspto-grants-2014_07
Patent number
US08785502B2

Reaction notes

Loading…